OncoMatch/Clinical Trials/NCT06505369
Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
Is NCT06505369 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for multiple myeloma.
Treatment: Daratumumab · Bortezomib · Lenalidomide · Dexamethasone · Talquetamab · Teclistamab — This is Phase 2, open-label, multicentre, non-randomised study evaluating participants with newly diagnosed MM eligible for high-dose therapy. The goal of the study is to determine if consolidation with T-cell redirectors - Talquetamab and Teclistamab in sequence will improve the response depth: increase MRD negative CR rate.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic therapy or stem cell transplantation for any plasma cell dyscrasia
Exception: emergency use of a short course (equivalent of dexamethasone 40 mg/day for a maximum 4 days) of corticosteroids before treatment
Prior or current systemic therapy or stem cell transplantation for any plasma cell dyscrasia, with the exception of emergency use of a short course (equivalent of dexamethasone 40 mg/day for a maximum 4 days) of corticosteroids before treatment.
Lab requirements
Blood counts
Hemoglobin ≥8 g/dL; Platelets ≥75×10^9/L; ANC ≥1.0×10^9/L
Kidney function
eGFR ≥30 mL/min
Liver function
AST and ALT ≤2.5×ULN; Total bilirubin <1.5×ULN
Have clinical laboratory values meeting the following criteria: Hemoglobin ≥8 g/dL; Platelets ≥75×10^9/L; ANC ≥1.0×10^9/L; AST and ALT ≤2.5×ULN; eGFR ≥30 mL/min; Total bilirubin <1.5×ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify